ArticleFrontiers in oncology2026
Primary sclerosing epithelioid fibrosarcoma of the iliac fossa: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sclerosing epithelioid fibrosarcoma (SEF) is an exceedingly rare and aggressive fibroblastic malignancy. Primary involvement of the retroperitoneal iliac fossa is exceptionally uncommon in the literature, and its nonspecific clinical features and overlapping imaging findings pose significant diagnostic challenges. Case presentation: This case report describes a 53-year-old man who presented with a large, painful, palpable mass in the right lower quadrant. Imaging revealed a well-circumscribed lesion in the right iliac fossa. Non-contrast-enhanced computed tomography (CT) showed heterogeneous low density, while contrast-enhanced CT demonstrated characteristic progressive enhancement. On magnetic resonance imaging (MRI), the lesion exhibited iso- to slightly hypointense signals on T1-weighted imaging, mixed hyperintensity on T2-weighted imaging, and remarkable heterogeneous restricted diffusion on diffusion-weighted imaging. The patient underwent radical surgical resection, and the diagnosis of SEF was confirmed by histopathological and immunohistochemical examinations. No evidence of recurrence or metastasis was observed during the short-term follow-up period. Clinical discussion: The uniqueness of this case lies in the primary iliac fossa location, which has been reported only once previously in the pathological literature. Preoperatively, differential diagnoses included solitary fibrous tumor, low-grade fibromyxoid sarcoma, and schwannoma, which were ruled out based on characteristic imaging and histopathological features. During 10 months of short-term follow-up, there was no evidence of local recurrence or distant metastasis. Conclusions: A deep-seated soft-tissue mass displaying heterogeneous T2 signal with hypointense collagenous areas and progressive enhancement should raise suspicion for sclerosing epithelioid fibrosarcoma, especially in atypical locations such as the iliac fossa. Definitive diagnosis requires histopathology and immunohistochemistry (MUC4), while long-term follow-up is essential to monitor late recurrence or metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.